Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 30.
doi: 10.1002/mdc3.70245. Online ahead of print.

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Jason Aldred  1 , Manon Bouchard  2 , Juan Carlos Martínez-Castrillo  3 , Michael J Soileau  4 , Amy M Spiegel  5 , Lars Bergmann  5 , Resmi Gupta  5 , Megha B Shah  5 , Pavnit Kukreja  5 , David G Standaert  6 , Stuart H Isaacson  7 , Tove Henriksen  8
Affiliations

Efficacy and Safety of Foslevodopa/Foscarbidopa Monotherapy in Patients with Parkinson's Disease

Jason Aldred et al. Mov Disord Clin Pract. .

Abstract

Background: As Parkinson's disease (PD) progresses, managing symptoms becomes increasingly difficult. Foslevodopa/foscarbidopa (LDp/CDp), a 24-hour/day continuous subcutaneous infusion of levodopa/carbidopa (LD/CD) prodrugs, improves motor complications. The feasibility and sustainability of LDp/CDp monotherapy warrants investigation.

Objective: The aim was to report the efficacy and safety of LDp/CDp monotherapy and combination therapy.

Methods: This post hoc analysis assessed patients with PD and ≥2.5 "Off" hours/day receiving LDp/CDp monotherapy or combination therapy in 3 trials: a 12-week randomized active-controlled trial (RCT) comparing LDp/CDp with oral immediate-release LD/CD (NCT04380142), a 52-week open-label trial of LDp/CDp (NCT03781167), and its 96-week open-label extension study (OLE; NCT04379050). Monotherapy was defined as receiving LDp/CDp without concomitant PD medications; combination therapy was defined as receiving LDp/CDp with other PD medications.

Results: In the RCT, 74 of 141 patients received LDp/CDp. The 52-week trial enrolled 244 patients; 129 entered the OLE. Of LDp/CDp-treated patients, 19 of 74 (25.7%) in the RCT, 49 of 244 (20.1%) in the 52-week trial, and 46 of 129 (35.7%) in the OLE received monotherapy. In the RCT, mean (standard deviation) change from baseline to week 12 in "Off" time was -4.5 (4.4) and -3.0 (3.5) hours for monotherapy and combination therapy, respectively; +4.1 (3.7) and +3.1 (3.6) hours for "On" time without troublesome dyskinesia; and +4.0 (3.6) and +4.0 (3.9) hours for "On" time without dyskinesia. Efficacy was similar in open-label trials. Improvements in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale Part II, 39-item Parkinson's Disease Questionnaire, Parkinson's Disease Sleep Scale-2 scores, and overall safety were comparable between monotherapy and combination therapy groups.

Conclusions: LDp/CDp monotherapy treatment may be suitable for up to 96 weeks.

Keywords: Parkinson's disease; foslevodopa/foscarbidopa; monotherapy; subcutaneous infusion.

PubMed Disclaimer

References

    1. Parent M, Parent A. Substantia nigra and Parkinson's disease: a brief history of their long and intimate relationship. Can J Neurol Sci 2010;37(3):313–319.
    1. Rosebraugh M, Voight EA, Moussa EM, et al. Foslevodopa/foscarbidopa: a new subcutaneous treatment for Parkinson's disease. Ann Neurol 2021;90(1):52–61.
    1. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine‐receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5(8):677–687.
    1. Constantin VA, Szász JA, Dulamea AO, Valkovic P, Kulisevsky J. Impact of infusion therapies on quality of life in advanced Parkinson's disease. Neuropsychiatr Dis Treat 2023;19:1959–1972.
    1. Malek N, Grosset DG. Medication adherence in patients with Parkinson's disease. CNS Drugs 2015;29(1):47–53.

Grants and funding

LinkOut - more resources